Glp-1 Mimetics and Autophagy in Diabetic Milieu: State-of-the-Art

Overview

Journal Curr Diabetes Rev

Publisher Bentham Science Publishers

Specialty Endocrinology

Date 2024 Feb 1

PMID 38299271

Authors

Habib Yaribeygi

Mina Maleki

Raul D Santos

Tannaz Jamialahmadi

Amirhossein Sahebkar

Affiliations

Soon will be listed here.

Abstract

The diabetic milieu is associated with cascades of pathophysiological pathways that culminate in diabetic complications and tissue injuries. Autophagy is an essential process mandatory for cell survival and tissue homeostasis by degrading damaged organelles and removing injured cells. However, it may turn into a pathological process in an aberrant mode in the diabetic and/or malignant milieu. Moreover, autophagy could serve as a promising therapeutic target for many complications related to tissue injury. Glp-1 mimetics are a class of newer antidiabetic agents that reduce blood glucose through several pathways. However, some evidence suggests that they can provide extra glycemic benefits by modulating autophagy, although there is no complete understanding of this mechanism and its underlying molecular pathways. Hence, in the current review, we aimed to provide new insights on the possible impact of Glp-1 mimetics on autophagy and consequent benefits as well as mediating pathways.

Citing Articles

Liuweizhiji Gegen-Sangshen beverage protects against alcoholic liver disease in mice through the gut microbiota mediated SCFAs/GPR43/GLP-1 pathway.

Tang M, Zhao L, Huang F, Wang T, Wu X, Chen S Front Nutr. 2024; 11:1495695.

PMID: 39734674 PMC: 11673767. DOI: 10.3389/fnut.2024.1495695.

Autophagy alterations in obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease: the evidence from human studies.

Jakubek P, Pakula B, Rossmeisl M, Pinton P, Rimessi A, Wieckowski M Intern Emerg Med. 2024; 19(5):1473-1491.

PMID: 38971910 PMC: 11364608. DOI: 10.1007/s11739-024-03700-w.

References

Rathmann W, Kuss O, Kostev K . Incidence of newly diagnosed diabetes after Covid-19. Diabetologia. 2022; 65(6):949-954. PMC: 8923743. DOI: 10.1007/s00125-022-05670-0. View

Forbes J, Cooper M . Mechanisms of diabetic complications. Physiol Rev. 2013; 93(1):137-88. DOI: 10.1152/physrev.00045.2011. View

Aman Y, Schmauck-Medina T, Hansen M, Morimoto R, Simon A, Bjedov I . Autophagy in healthy aging and disease. Nat Aging. 2021; 1(8):634-650. PMC: 8659158. DOI: 10.1038/s43587-021-00098-4. View

Klionsky D, Petroni G, Amaravadi R, Baehrecke E, Ballabio A, Boya P . Autophagy in major human diseases. EMBO J. 2021; 40(19):e108863. PMC: 8488577. DOI: 10.15252/embj.2021108863. View

Piffoux M, Eriau E, Cassier P . Autophagy as a therapeutic target in pancreatic cancer. Br J Cancer. 2020; 124(2):333-344. PMC: 7852577. DOI: 10.1038/s41416-020-01039-5. View

Kiruthiga C, Devi K, Nabavi S, Bishayee A . Autophagy: A Potential Therapeutic Target of Polyphenols in Hepatocellular Carcinoma. Cancers (Basel). 2020; 12(3). PMC: 7139730. DOI: 10.3390/cancers12030562. View

Zhao H, Wang Y, Qiu T, Liu W, Yao P . Autophagy, an important therapeutic target for pulmonary fibrosis diseases. Clin Chim Acta. 2019; 502:139-147. DOI: 10.1016/j.cca.2019.12.016. View

Zhang W, Li X, Wang S, Chen Y, Liu H . Regulation of TFEB activity and its potential as a therapeutic target against kidney diseases. Cell Death Discov. 2020; 6:32. PMC: 7195473. DOI: 10.1038/s41420-020-0265-4. View

Phadwal K, Feng D, Zhu D, Macrae V . Autophagy as a novel therapeutic target in vascular calcification. Pharmacol Ther. 2019; 206:107430. DOI: 10.1016/j.pharmthera.2019.107430. View

10.

Yaribeygi H, Rashidy-Pour A, Atkin S, Jamialahmadi T, Sahebkar A . GLP-1 mimetics and cognition. Life Sci. 2020; 264:118645. DOI: 10.1016/j.lfs.2020.118645. View

11.

Barnett A . The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide. Diabetes Obes Metab. 2011; 14(4):304-14. PMC: 3488291. DOI: 10.1111/j.1463-1326.2011.01523.x. View

12.

Yaribeygi H, Maleki M, Nasimi F, Jamialahmadi T, Stanford F, Sahebkar A . Benefits of GLP-1 Mimetics on Epicardial Adiposity. Curr Med Chem. 2023; 30(37):4256-4265. PMC: 10293101. DOI: 10.2174/0929867330666230113110431. View

13.

Yaribeygi H, Sathyapalan T, Sahebkar A . Molecular mechanisms by which GLP-1 RA and DPP-4i induce insulin sensitivity. Life Sci. 2019; 234:116776. DOI: 10.1016/j.lfs.2019.116776. View

14.

Sattar N, Lee M, Kristensen S, Branch K, Del Prato S, Khurmi N . Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021; 9(10):653-662. DOI: 10.1016/S2213-8587(21)00203-5. View

15.

Candeias E, Sebastiao I, Cardoso S, Carvalho C, Santos M, Oliveira C . Brain GLP-1/IGF-1 Signaling and Autophagy Mediate Exendin-4 Protection Against Apoptosis in Type 2 Diabetic Rats. Mol Neurobiol. 2017; 55(5):4030-4050. DOI: 10.1007/s12035-017-0622-3. View

16.

Ashrafizadeh M, Yaribeygi H, Atkin S, Sahebkar A . Effects of newly introduced antidiabetic drugs on autophagy. Diabetes Metab Syndr. 2019; 13(4):2445-2449. DOI: 10.1016/j.dsx.2019.06.028. View

17.

Cai X, She M, Xu M, Chen H, Li J, Chen X . GLP-1 treatment protects endothelial cells from oxidative stress-induced autophagy and endothelial dysfunction. Int J Biol Sci. 2018; 14(12):1696-1708. PMC: 6216037. DOI: 10.7150/ijbs.27774. View

18.

Li X, Li C, Zhang L, Wu M, Cao K, Jiang F . The significance of exosomes in the development and treatment of hepatocellular carcinoma. Mol Cancer. 2020; 19(1):1. PMC: 6942270. DOI: 10.1186/s12943-019-1085-0. View

19.

Deter R, DE DUVE C . Influence of glucagon, an inducer of cellular autophagy, on some physical properties of rat liver lysosomes. J Cell Biol. 1967; 33(2):437-49. PMC: 2108350. DOI: 10.1083/jcb.33.2.437. View

20.

Yim W, Mizushima N . Lysosome biology in autophagy. Cell Discov. 2020; 6:6. PMC: 7010707. DOI: 10.1038/s41421-020-0141-7. View